These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8839556)

  • 1. Graft-versus-host disease. Possible higher risk for African American patients.
    Easaw SJ; Lake DE; Beer M; Seiter K; Feldman EJ; Ahmed T
    Cancer; 1996 Oct; 78(7):1492-7. PubMed ID: 8839556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.
    Hahn T; McCarthy PL; Zhang MJ; Wang D; Arora M; Frangoul H; Gale RP; Hale GA; Horan J; Isola L; Maziarz RT; van Rood JJ; Gupta V; Halter J; Reddy V; Tiberghien P; Litzow M; Anasetti C; Pavletic S; Ringdén O
    J Clin Oncol; 2008 Dec; 26(35):5728-34. PubMed ID: 18981462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study.
    Ruutu T; Volin L; Parkkali T; Juvonen E; Elonen E
    Blood; 2000 Oct; 96(7):2391-8. PubMed ID: 11001889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation.
    Tseng LH; Lin MT; Hansen JA; Gooley T; Pei J; Smith AG; Martin EG; Petersdorf EW; Martin PJ
    Blood; 1999 Oct; 94(8):2911-4. PubMed ID: 10515896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation.
    Ghalie R; Fitzsimmons WE; Weinstein A; Manson S; Kaizer H
    Ann Pharmacother; 1994 Mar; 28(3):379-83. PubMed ID: 8193430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
    Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
    Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis.
    Ruutu T; Nihtinen A; Niittyvuopio R; Juvonen E; Volin L
    Cancer; 2018 Feb; 124(4):727-733. PubMed ID: 29112242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
    Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.
    Deeg HJ; Lin D; Leisenring W; Boeckh M; Anasetti C; Appelbaum FR; Chauncey TR; Doney K; Flowers M; Martin P; Nash R; Schoch G; Sullivan KM; Witherspoon RP; Storb R
    Blood; 1997 May; 89(10):3880-7. PubMed ID: 9160697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
    Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K
    Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus.
    Larsson K; Aschan J; Remberger M; Ringdén O; Winiarski J; Ljungman P
    Transplantation; 2004 Feb; 77(4):526-31. PubMed ID: 15084929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome.
    Weisdorf D; Haake R; Blazar B; Miller W; McGlave P; Ramsay N; Kersey J; Filipovich A
    Blood; 1990 Feb; 75(4):1024-30. PubMed ID: 2302454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
    Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
    Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.
    Locatelli F; Zecca M; Rondelli R; Bonetti F; Dini G; Prete A; Messina C; Uderzo C; Ripaldi M; Porta F; Giorgiani G; Giraldi E; Pession A
    Blood; 2000 Mar; 95(5):1572-9. PubMed ID: 10688810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate.
    Kanda Y; Izutsu K; Hirai H; Sakamaki H; Iseki T; Kodera Y; Okamoto S; Mitsui H; Iwato K; Hirabayashi N; Furukawa T; Maruta A; Kasai M; Atsuta Y; Hamajima N; Hiraoka A; Kawa K
    Leukemia; 2004 May; 18(5):1013-9. PubMed ID: 15029208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.